Cancer
Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN/Docetaxel trial
Published in Cancer Weekly, August 7th, 2007
Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has commenced patient enrolment in its U.K. clinical trial to evaluate the anti-tumour effects of systemic administration of REOLYSIN(R) in combination with docetaxel (Taxotere(R)) in patients with advanced cancers including bladder, prostate, lung and upper gastro-intestinal. In preclinical studies, the combination of REOLYSIN(R) and various taxanes including docetaxel has been shown to be synergistic against a variety of cancer cell lines.
"Taxanes are widely used in the treatment of cancer but have the potential to be significantly more efficacious when used with REOLYSIN(R), which has already shown...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-08-07)
More Articles from Cancer Weekly
- Cancer Gene Therapy
"Preconditioning" Helps Protect Brain's Blood Vessels from Stroke - Cancer Gene Therapy
Pediatric Ritalin Use May Affect Developing Brain - Cancer Vaccines
Gene-Transcription Machinery Seen Poised for Action, Held in Check Until Needed - Bladder Cancer
Pro-Pharmaceuticals Announces Boston Medical Center Dosing Patients with DAVANAT in Advanced Biliary Cancer Trial - Brain Cancer
A Substantial Opportunity Exists for Second-Line Chemotherapy to Enter the Primary Brain Cancer Market - Breast Cancer
American Medical Association Approves CPT Code for Electronic Brachytherapy for Treatment of Early Breast Cancer - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
